Cited 0 times in
Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강영애 | - |
dc.contributor.author | 김송이 | - |
dc.contributor.author | 김영삼 | - |
dc.contributor.author | 김은영 | - |
dc.contributor.author | 박무석 | - |
dc.contributor.author | 이상훈 | - |
dc.contributor.author | 이수환 | - |
dc.contributor.author | 이은혜 | - |
dc.contributor.author | 임아영 | - |
dc.contributor.author | 장준 | - |
dc.contributor.author | 정경수 | - |
dc.contributor.author | 정지예 | - |
dc.contributor.author | 최지수 | - |
dc.contributor.author | 곽세현 | - |
dc.date.accessioned | 2021-05-21T16:45:42Z | - |
dc.date.available | 2021-05-21T16:45:42Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182553 | - |
dc.description.abstract | Purpose: Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes. However, definitive guidelines on an optimal treatment regimen and duration for Hr-TB are currently under discussion. We evaluated the characteristics and treatment outcomes of Hr-TB patients. Materials and methods: We retrospectively reviewed the medical records of Hr-TB patients treated at a South Korean tertiary referral hospital from January 2005 to December 2018. Results: We included 195 Hr-TB patients. 113 (57.9%) were male, and the median age was 56.6 [interquartile range, 40.2-68.6] years. Mutations in katG were the most frequent [54 (56.3%)], followed by those in the inhA [34 (35.4%)]. Favorable and unfavorable outcomes were noted in 164 (84.1%) and 31 (15.9%) patients, respectively. Smoking history [odds ratio (OR)=5.606, 95% confidence interval (CI): 1.695-18.543, p=0.005], low albumin level (OR=0.246, 95% CI: 0.104-0.578, p=0.001), and positive acid-fast bacilli culture at 2 months (OR=7.853, 95% CI: 1.246-49.506, p=0.028) were associated with unfavorable outcomes. Conclusion: A tailored strategy targeting high-risk patients is imperative for improved treatment outcomes. Further research on the rapid and accurate detection of resistance to INH and other companion drugs is warranted. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antitubercular Agents / pharmacology | - |
dc.subject.MESH | Antitubercular Agents / therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Isoniazid / pharmacology | - |
dc.subject.MESH | Isoniazid / therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Mycobacterium tuberculosis / drug effects | - |
dc.subject.MESH | Mycobacterium tuberculosis / genetics | - |
dc.subject.MESH | Mycobacterium tuberculosis / isolation & purification* | - |
dc.subject.MESH | Prevalence | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tuberculosis / drug therapy | - |
dc.subject.MESH | Tuberculosis, Multidrug-Resistant / drug therapy* | - |
dc.title | Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Se Hyun Kwak | - |
dc.contributor.googleauthor | Ji Soo Choi | - |
dc.contributor.googleauthor | Eun Hye Lee | - |
dc.contributor.googleauthor | Su Hwan Lee | - |
dc.contributor.googleauthor | Ah Young Leem | - |
dc.contributor.googleauthor | Sang Hoon Lee | - |
dc.contributor.googleauthor | Song Yee Kim | - |
dc.contributor.googleauthor | Kyung Soo Chung | - |
dc.contributor.googleauthor | Eun Young Kim | - |
dc.contributor.googleauthor | Ji Ye Jung | - |
dc.contributor.googleauthor | Moo Suk Park | - |
dc.contributor.googleauthor | Young Sam Kim | - |
dc.contributor.googleauthor | Joon Chang | - |
dc.contributor.googleauthor | Young Ae Kang | - |
dc.identifier.doi | 10.3349/ymj.2020.61.12.1034 | - |
dc.contributor.localId | A00057 | - |
dc.contributor.localId | A00626 | - |
dc.contributor.localId | A00707 | - |
dc.contributor.localId | A00811 | - |
dc.contributor.localId | A01457 | - |
dc.contributor.localId | A02836 | - |
dc.contributor.localId | A02904 | - |
dc.contributor.localId | A03053 | - |
dc.contributor.localId | A03382 | - |
dc.contributor.localId | A03472 | - |
dc.contributor.localId | A03570 | - |
dc.contributor.localId | A03735 | - |
dc.contributor.localId | A05057 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 33251777 | - |
dc.subject.keyword | Tuberculosis | - |
dc.subject.keyword | isoniazid | - |
dc.subject.keyword | treatment outcome | - |
dc.contributor.alternativeName | Kang, Young Ae | - |
dc.contributor.affiliatedAuthor | 강영애 | - |
dc.contributor.affiliatedAuthor | 김송이 | - |
dc.contributor.affiliatedAuthor | 김영삼 | - |
dc.contributor.affiliatedAuthor | 김은영 | - |
dc.contributor.affiliatedAuthor | 박무석 | - |
dc.contributor.affiliatedAuthor | 이상훈 | - |
dc.contributor.affiliatedAuthor | 이수환 | - |
dc.contributor.affiliatedAuthor | 이은혜 | - |
dc.contributor.affiliatedAuthor | 임아영 | - |
dc.contributor.affiliatedAuthor | 장준 | - |
dc.contributor.affiliatedAuthor | 정경수 | - |
dc.contributor.affiliatedAuthor | 정지예 | - |
dc.contributor.affiliatedAuthor | 최지수 | - |
dc.citation.volume | 61 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1034 | - |
dc.citation.endPage | 1041 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.61(12) : 1034-1041, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.